Ignite Creation Date:
2024-10-25 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06563778
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-19
Brief Title:
ChidamideDecitabine Plus Anti-PD-1 Antibody for Patients With RR cHL Who Are Transplant-ineligible or Refused Transplant
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Open-label Phase 2 Trial of ChidamideDecitabine Plus Anti-PD-1 Antibody for Patients With RR cHL Who Are Transplant-ineligible or Refused Transplant
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The prognosis for patients with relapsedrefractory classical Hodgkin lymphoma cHL who refuse or are ineligible for transplant is poor This open label randomized phase 2 study aims to evaluate the efficacy of ChidamideDecitabine plus Anti-PD-1 Antibody and Brentuximab Vedotin Bendamustine plus Anti-PD-1 Antibody in transplant-ineligible or refused transplant diagnosed RR cHL The primary objective of the study is to evaluate progression-free survival
Detailed Description:
The prognosis of refractory or early-relapsed lymphoma is poor and it is even worse for those who are not eligible or refuse transplantation Although many salvage regimens have been developed there is no standard of care Preliminary clinical observations have shown that Chidamide Decitabine plus Anti-PD-1 Antibody might be beneficial for these patients Brentuximab Vedotin or Bendamustine plus Anti-PD-1 Antibody are both standard regimensThe combination of Brentuximab Vedotin Bendamustine and Anti-PD-1 Antibody may be another effective regimen This open-label randomized phase 2 study aims to evaluate the efficacy of ChidamideDecitabine plus anti-PD-1 antibody and Brentuximab Vedotin Bendamustine plus Anti-PD-1 Antibody in patients with classical Hodgkin lymphoma who are transplant-ineligible or refused transplant
The primary objective of the study is to evaluate the progression free survival The key secondary end points are complete response rate objective response rate and the safety
The primary objective of the study is to evaluate the progression free survival The key secondary end points are complete response rate objective response rate and the safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None